1 Parapneumonic effusions related to Streptococcus pneumoniae: serotype and disease 2 severity trends Catherine Hyams^{1,2}, David T Arnold¹, Robyn Heath², Zahin Amin-Chowdhury⁵, David 3 Hettle^{3,4}, Gabriella Ruffino¹, Paul North^{3,4}, Charlotte Grimes¹, Norman K Fry⁵, Philip 4 Williams^{3,4}, Leon Danon⁶, O Martin Williams^{3,4}, Shamez Ladhani⁵, Adam Finn⁶, Nick A 5 Maskell¹ 6 7 ¹ Academic Respiratory Unit, Learning and Research, Southmead Hospital, Bristol BS10 8 9 5NB, United Kingdom ² Vaccine and Testing Research Team, Clinical Research Facility, St Michael's Hill, Bristol 10 Royal Infirmary, Bristol, United Kingdom 11 12 ³ Microbiology Services Bristol, Bristol Royal Infirmary, Bristol, United Kingdom ⁴ Department of Microbiology, University Hospitals Bristol NHS Foundation Trust, Bristol 13 14 Royal Infirmary, Bristol, UK, BS2 8HW 15 ⁵ National Infection Service, UKHSA, London, United Kingdom ⁶Engineering Mathematics, University of Bristol, Bristol, United Kingdom 16 17 ⁷ Bristol Vaccine Centre, Schools of Cellular and Molecular Medicine and of Population 18 Health Sciences, University of Bristol, Bristol, BS2 8AE, United Kingdom 19 20 **Corresponding address:** Dr Catherine Hyams, MBBS BSc(Hons) PhD MRCP 21 Academic Respiratory Unit, 22 Learning & Research Building, 23 Southmead Hospital, Bristol, 24 BS10 5NB 25 catherine.hyams@bristol.ac.uk 26 **Keywords:** Streptococcus pneumoniae, pneumococcus, respiratory 27 infection, pleural disease, serotypes 28 Take home message: Pneumococcal parapneumonic effusions show increasing 29 incidence despite PCV introduction, with serotype 1 and 3 persisting and increase in non-PCV13 disease. Pleural infection 30 31 showed lower mortality than SPE, and baseline RAPID score 32 predicted 90-day mortality. 33

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

ABSTRACT Introduction Streptococcus pneumoniae epidemiology is changing in response to vaccination and some data suggest empyema incidence is increasing. However, differences exist between UK and USA studies. We describe trends in the clinical phenotype of adult pneumococcal pleural infection, including simple parapneumonic effusions (SPE) in the pneumococcal conjugate vaccination (PCV) era. Methods Retrospective cohort study, all adults ≥16 years admitted to three large UK hospitals, 2006-2018 with pneumococcal disease. Medical records were reviewed for each clinical episode. Serotype data were obtained from the UKHSA national reference laboratory. **Results** 2477 invasive pneumococcal cases were identified: 459 SPE and 100 pleural infection cases. Incidence increased over time, including non-PCV-serotype disease. PCV7-serotype disease declined following paediatric PCV7 introduction, but the effect of PCV13 was less apparent as disease caused by the additional six serotypes plateaued with serotypes 1 and 3 causing such parapneumonic effusions from 2011 onwards. Mortality was lower in pleural infection patients than SPE patients. Patients with frank pus had lower mortality then those without. 90-day mortality could be predicted by baseline increased RAPID score. Conclusion Pneumococcal infection continues to cause severe disease despite the introduction of PCVs. The predominance of serotype 1 and 3 in this adult UK cohort is in keeping with previous

57 studies in paediatric and non-UK studies. Rising non-PCV serotype disease and limited

impact of PCV13 on cases caused by serotypes 1 and 3 offset the reductions in adult

pneumococcal parapneumonic effusion disease burden observed following introduction of the

60 childhood PCV7 programme.

58

59

INTRODUCTION

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

Streptococcus pneumoniae remains the leading bacterial cause of community-acquired pneumonia (CAP), despite vaccine deployment. A dose of PneumoVax® (unconjugated 23valent polysaccharide vaccine, PPV23) is offered to all adults from age 65 years in the UK and ≥2-year-olds with at least one clinical risk factor for pneumococcal disease also receive this vaccine [1]. The 7-valent pneumococcal conjugate vaccine (PCV) (PCV7) was introduced into the UK childhood vaccination programme in 2006 on a 2 priming dose schedule with a booster following the first birthday (2+1) and subsequently replaced in April 2010 with a 13-valent PCV (PCV13). The schedule was modified to 1+1 in 2020. Several USA studies have shown that PCV introduction resulted in a significant reduction in both carriage and invasive pneumococcal disease (IPD) due to vaccine serotypes, especially in children [2, 3] although an increase in pneumococcal empyema cases in children has been reported [4] and the effect of paediatric PCV deployment on adult disease phenotype is debated [5]. By 2016/17, UK surveillance demonstrated that PCV7 serotype disease in children had virtually disappeared, with significant reduction in PCV7 disease burden in adults. In contrast, while PCV13 serotype disease incidence has not disappeared across all age groups, but plateaued, with a remaining residual incidence of 7.97 per 100,000 across all age groups. There has also been an increase in disease attributable to non-PCV13 serotypes, especially in the elderly, which has reduced overall disease reduction resulting from vaccine introduction [6-8]. Evidence from a large pneumococcal pneumonia patient cohort in Nottingham, UK suggests that, aside from age, residential care status and some comorbidities, there are relatively few differences between patients with disease caused by PCV13 and those with non-PCV13 serotype infections [9].

Approximately 15-20% hospitalised pneumococcal CAP cases are associated with a pleural effusion [10, 11] and 6% with empyema [10, 12]. However, recent evidence suggests that incidence of pneumococcal empyema has increased following paediatric PCV deployment, especially in adults aged >65 years, possibly due to serotype 1 emergence [13]. Thus, vaccine-driven serotype replacement may be leading to changes in pneumococcal disease phenotype and severity. This is a concern as morbidity and mortality associated with simple parapneumonic effusion (SPE) are higher than with uncomplicated pneumonia [14].

Here we present the largest cohort of patients with a single-organism pleural infection, encompassing SPE and pleural infection (complex parapneumonic effusion (CPE) or empyema) attributable to pneumococcus, in a single-centre observational study covering thirteen years during which PCVs were introduced into the UK paediatric vaccination programme. We sought to determine whether there were any differences in pneumococcal disease presentation and severity associated with empyema, given concerns surrounding changing pneumococcal serotype distribution.

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

MATERIALS AND METHODS **Study Subjects** Patients aged ≥16 years admitted to all three hospitals providing emergency care in Bristol and Bath (University Hospitals Bristol and Weston, North Bristol and The Royal United Hospital NHS Trusts) between January 2006 and December 2018, with a confirmed microbiological diagnosis of pneumococcal infection were eligible for this study. This study was approved by the Health Research Authority, UK (IRAS 265437). **Study Design** A retrospective cohort study at three large NHS hospitals in the UK. Methods Study-eligible cases were identified retrospectively by searching the Laboratory Information Management System (LIMS) database (Clinisys WinPath Enterprise). S. pneumoniae was confirmed on culture from blood at a central laboratory using standard microbiological techniques outlined in UK standards for microbiology investigations combined with API®-20 Strep (BioMérieux, UK) or MALDI-TOF (matrix-assisted laser desorption/ionisation/time of flight) mass spectrometry (Bruker, UK) [15]. A positive pneumococcal urinary-antigen test (BinaxNOW®, Alere, UK) was also considered confirmative of pneumococcal infection. Confirmed cases were linked with the UK Health Security Agency (UKHSA) national reference laboratory to obtain serotype data [16] which were collected separately from

clinical data to avoid any risk of bias in data collection. Pneumococcal serotypes were

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

grouped by PCV (PCV7; PCV13-7 representing the additional 6 serotypes in PCV13; and PCV13) or as non-PCV (Supplementary Data 1). Patients with pneumococcal infection and a pleural effusion on radiology were either classified as: (1) pleural infection (empyema/CPE): if fluid was pus and/or bacterial culture positive, and/or there was an effusion relating to pneumonia and requiring definitive drainage (e.g. intercostal catheter insertion or thoracic surgery), and/or there was an exudative effusion with pH \leq 7.2; or as, (2) SPE: an exudative effusion not classified as either an empyema or CPE in a patient with a clinical and/or radiological diagnosis of pneumonia. Patients' clinical records were reviewed at each hospital and data, including clinical outcomes, recorded. The vaccination status of each patient was established from electronically linked GP records [15]. The CURB65 severity score on admission was calculated for each clinical episode [17]. Patients with pleural infection had a RAPID (Renal, Age, Purulence, Infection source, and Dietary factors) score calculated [18], which has been validated to stratify adults with pleural infection according to increasing risk of mortality [19]. Analysis Patient data are reported as medians and interquartile ranges (IQR) for continuous variables. Categorical variables are presented as counts and percentages. Baseline characteristics and comorbid risk factors for SPE and pleural infection were compared using Fisher's exact tests for categorical variables, and the Mann-Whitney U-test for non-parametric continuous

variables. The Kaplan–Meier method and Cox proportional hazard regression model were used for calculation of survival over time, while survival differences were analyzed using the log-rank test. Statistical analysis was performed using SPSS, version 28.0 (New York, IBM). Graphs were generated in GraphPad PRISM, version 9.0.

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

RESULTS 2657 IPD episodes were identified, of which 2447 were respiratory infections: 1888 pneumonia cases, 459 SPE and 100 cases of pleural infection (Figure 1). 283/559 (51%) cases with parapneumonic effusion had S. pneumoniae confirmed on blood culture. In total, 282/559 (50%) were male with a median age of 68y (IQR 50-78) (Table 1, Supplementary Data 2). Pre-existing cardiac and respiratory disease was common in patients with parapneumonic effusions. Patients with pleural infection were younger than those with SPE (median ages 55 vs 69y respectively, P<0.001), and were more likely to have history of alcohol misuse and/or intravenous drug usage (P<0.05) and less likely to develop acute renal failure (P<0.05). On presentation to hospital, neither clinical observations nor CURB65 score differed significantly between patients with SPE and pleural infection (P > 0.05); in contrast, patients with pleural infection had both a significantly greater neutrophilia (P<0.01) and more elevated CRP levels (*P*<0.001) (Table 1, Supplementary Data 2 and 3). Annual incidence of S. pneumoniae parapneumonic effusions increased throughout the study period (Figure 2A). There was a 33% and 34% increase in unplanned hospital admissions and microbiological testing between 2006 and 2018 (Supplementary Data 4, indicating relative increase in hospital workload was not equivalent to the increase in disease incidence. The age of patients admitted throughout the study did not show any apparent trend (Supplementary Data 5). In 38% cases serotype was available, of which overall 52% were attributable to a PCV13 serotype while only 8% were caused by a non-vaccine serotype. Over the study period, there was an absolute and proportional decrease in disease caused by PCV7 serotypes. All parapneumonic effusions caused by a PCV7 serotype after 2011 were SPE (serotypes 14 and 19F), with no pleural infections caused by a PCV7 serotype after 2011. PCV13-7 disease

showed an initial rise, followed by a fall after PCV13 introduction with a gradual rise in

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

disease over the last 5 study years (Figure 2B). Following the introduction of PCV13 in 2010, the only PCV13-7 serotypes that caused pneumococcal pleural infections were 1 and 3: 2 (17% of serotype known disease) and 3 (25%) pre-2010 pleural infection cases versus 9 (30%) and 7 (23%) post-2010 pleural infection cases due to serotype 1 and 3 respectively. Serotype 1 affected younger patients and was associated with a different RAPID severity group distribution than seen in patients with serotype 3 parapneumonic effusions (Table 2). Overall, 19% patients with pneumococcal parapneumonic effusions died within 90-days of presentation (Table 1, Supplementary Table 6). Patients with pleural infections had higher survival rates than those with SPE at 30-, 90- and 365-days (P<0.01) (Figure 3A). Median survival was 468 days (340-590 days, 95% CI) in patients with pleural infection, vs 286 (274-335 days, 95% CI) in those with SPE. In total, 59/100 (59%) pleural infection patients had pus and these patients had improved 30-, 90-, and 365-day mortality compared to those without pus; in contrast, loculation was associated with reduced 30-, 90- and 365-day mortality (Table 4). Surgical management was associated with improved prognosis: no deaths occurred within 1-year of presentation compared to 24% mortality in patients with pleural infection who did not undergo surgery. Patients undergoing thoracic surgery were younger than those who did not (median age 45 years, IQR40-52 versus 66 years, IQR 53-78). The mortality rate among patients with pleural infection increased alongside RAPID score severity at 30-, 90- and 365-days (Figure 3B, Table 3), and a high RAPID score was associated with a median survival of 56 days (20-154 days, 95% CI). Proportional hazards regression analysis confirmed that more severe RAPID group was associated with increased 90-day (P=0.046, 95% CI 1.02-16.54) and 365-day mortality (P=0.012, 95% CI 1.29-7.79) (Table 4).

DISCUSSION

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

This observational cohort study, with data from a 13-year period spanning PCV introduction into the UK childhood vaccination programme, shows an increasing incidence of adult pneumococcal parapneumonic effusions. An increasing incidence of pneumococcal disease has also been reported by other UK studies [9, 16, 20, 21], with Pick et al reporting incidence of pneumococcal pneumonia of 32.2 and 48.2 per 100,000 population in 2013 and 2018 respectively [9]. Using previously published estimates that up to 20% of adults hospitalised with pneumococcal pneumonia develop a pleural effusion [10, 11], estimates of parapneumonic effusion incidence from that study would be 6.4 and 9.6 in 2013 and 2018, which are similar to the incidence rates of 5.0 and 9.8 observed in the same years in this study. Recent national epidemiological studies of pleural infection from North America also show significant increases in pleural infection rates both in children [22] and adults [23]. Likewise, a Danish study from 1997-2001, showed steadily rising pleural infection rates in the elderly [24] and a UK study showed annual rises in adult pleural infections from 2008-17 [25], most marked in over 60-year-old individuals with a 194% increase over the decade. Both overall admissions and microbiological testing at the study hospitals increased progressively during our study period, but not as much as disease incidence, suggesting this did not solely account for the increasing incidence observed. Whilst the study period encompassed a time when the UK vaccination programme changed, there was also an expanding total and older adult population in Bath and Bristol. Furthermore, there may have been changes in patient or physician treatment preferences, including threshold for referral to secondary care, diagnostic testing and treatment which may have impacted the incidence of disease estimated throughout this study [26].

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

The introduction of PCV7 into the UK childhood vaccination programme in 2006 was followed by a decrease in adult pneumococcal pleural effusions attributable to PCV7 vaccine serotypes in this study. Notably, all parapneumonic effusions due to PCV7 serotypes after 2011 were SPE and due to serotypes 14 and 19F, with no cases of pleural infection. However, PCV13 introduction in 2010 did not result in such a marked indirect reduction in disease caused by the additional six serotypes in PCV13 due to the persistence of serotype 1 or 3 disease. This partially aligns with national serotype trends, showing reductions in both PCV7 serotype and serotype 1 adult IPD incidence [6], and both serotypes are prevalent in studies of pleural infection in children [27]. In the UK, large reductions in vaccine-serotype adult IPD were offset by increases in non-PCV13 IPD [6, 16, 20], a trend also apparent in this patient cohort, with non-PCV13 disease increasing from 30% to 60% of known serotype disease. Pick et al showed an increase in non-PCV13 serotype pneumococcal pneumonia from 2014/15 onwards [9] as well as an overall increase in PCV13-7 serotype disease, in contrast to trends reported in this study. These are the first data on serotype trends in adult pneumococcal pleural disease since paediatric PCV introduction in the UK. Serotype affects pneumococcal resistance to innate immunity, duration of nasopharyngeal colonisation, the number of episodes of invasive disease per colonisation event, morality and disease severity [28-30]. The two PCV13-7 serotypes which continued to cause pneumococcal pleural infection following PCV13 introduction are notable serotypes as they have unusual polysaccharide capsules. Serotype 1 expresses a zwitterionic and structurally diverse polysaccharide capsule, which uniquely may act as a T-cell dependent antigen [31]. This serotype rarely causes asymptomatic nasopharyngeal colonization but is a commonly isolated in IPD [28], and frequently causes invasive pneumonia [32]. Studies suggests serotype 1 is more likely to be identified in young patients, and in some studies it is the most

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

frequent cause of pneumococcal pleural infection, with increasing empyema incidence attributable to this serotype [11, 13]. In contrast, the serotype 3 polysaccharide capsule is large, resulting in a highly mucoid appearance, and is one of a few capsules produced by synthase-mediated synthesis [33]. Serotype 3 also causes considerable disease burden [11, 27] being the most common overall cause of pneumonia in the USA [34], is highly invasive [28] and is associated with increased mortality [29]. Distinct lineages exist within serotype 3 clonal complex 180, and recent clade distributions shift has led to the emergence and expansion of clade II [35, 36], which now represents 50% serotype 3 IPD in the UK [37]. We could not determine serotype 3 clade grouping in this analysis, but clade II emergence may, at least in part, explain serotype 3 disease persistence. Overall, pre-existing medical conditions were commonly present amongst adults with pneumococcal parapneumonic effusions, although the median patient age was lower than that seen in other cohorts of parapneumonic effusions [12, 25]. Uniquely, this cohort of parapneumonic effusion cases were all attributable to pneumococcal infection, which may cause the condition in younger patients than other pathogens [25, 38]. Despite this, the burden of pre-existing medical comorbidity was equivalent: both SPE and pleural infection patients had significant cardiac (44%) and respiratory (43%) conditions predominating. A large systematic review found that 72% of patients with pleural infection had at least one significant comorbidity, with high levels of pre-existing cardiac (19%) and respiratory (20%) diseases [38]. Excessive alcohol consumption was significantly more common among pleural infection cases, in line with other published cohort studies [14]. Alcohol abuse may predispose to the development of pleural infection through its general immunosuppressive effect in addition to associated increases in risk of aspiration and delayed presentation to medical services [12].

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

As shown in the initial validation and subsequent cohort studies of the RAPID score [18, 19], a high score was strongly associated with the risk of mortality by 3-months. Study patients in the low-risk group had a 3% (95% C.I 0.7 to 15%) risk of 90-day mortality compared to 57% (95% C.I. 28% to 82% P<0.01), for those with a high risk score, while there was much less difference in survival between those in low and medium RAPID groups, as reported by others [19, 39]. There was a positive association between pleural fluid purulence and survival: this relationship has been demonstrated in cohorts that were not restricted by causative organism, suggesting it is disease and not pathogen specific [18]. Anecdotal report findings suggest effusions comprised of frank pus tend to be non-loculated and therefore more readily drained. This study identified patients with pneumococcal infection and parapneumonic effusions within a defined geographical area, covering a population of approximately one million adults, and encompassed 3 large hospitals with 100,000 unplanned adult admissions annually. One of these hospitals is the regional thoracic surgery centre, whilst another has a specialist pleural disease service, possibly increasing the accuracy of the clinical data presented here. We captured disease and serotype trends over 13 years, spanning PCV introduction. By linking with the UKHSA national reference laboratory we were able to report serotype where it was available. Importantly, the epidemiological data were supported with detailed clinical information for individual patients, including short- and long-term outcomes. However, this study also has limitations. This is a retrospective observational study; therefore, only information documented in clinical records could be included and patients were managed at the discretion of individual physicians. As a regional study, the findings here may not be representative of other populations; although, our serotype trends are comparable to other UK

national and regional reports. We included patients who tested positive for pneumococcus using the BinaxNOW® urinary antigen test, which has a known sensitivity of 65% and prolonged positive test result after exposure to pneumococcus [40]. Lastly, different methodologies were used to identify pneumococcal serotypes during the study period; whole genomic sequencing was only routinely used by UKHSA from October 2017, and therefore earlier isolates did not have this performed.

Overall, we found an increasing incidence of pneumococcal parapneumonic effusion in Bristol and Bath, UK. The proportion of disease attributable to PCV7 serotypes fell after 2006, when the PCV7 vaccine was introduced into the UK childhood vaccination programme; importantly, no cases of PCV7 pleural infection occurred in adults after 2011. However, disease attributable serotypes 1 and 3 did not show decline following PCV13 vaccine rollout. Further research is needed to determine if *S. pneumoniae* serotype is predictive of mortality risk in adults with pneumococcal parapneumonic effusions.

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

ACKNOWLEDGEMENTS The authors would like to acknowledge the research teams at The Royal United, North Bristol and University Hospitals of Bristol and Weston NHS Trusts. **COMPETING INTERESTS** CH is Principal Investigator of the AvonCAP study which is an investigator-led University of Bristol study funded by Pfizer. AF is a member of the Joint Committee on Vaccination and Immunization (JCVI) and chair of the World Health Organization European Technical Advisory Group of Experts on Immunization (ETAGE) committee. In addition to receiving funding from Pfizer as Chief Investigator of this study, he leads another project investigating transmission of respiratory bacteria in families jointly funded by Pfizer and the Gates Foundation. The other authors have no relevant conflicts of interest to declare. **CONTRIBUTORSHIP STATEMENT** CH, DA, AF, OMW and NM generated the research questions and analysis plan. CH, RH, DH, GF, DA, PN, PW, ZAC collected data. CH and DH verified the data. CH, DA, RH, AF and NM undertook the data analysis. AF, OMW and NM provided oversight of the research. All authors contributed to the preparation of the manuscript and its revision for publication and had responsibility for the decision to publish. **FUNDING** CH was funded by the National Institute for Health Research [NIHR Academic Clinical Fellowship (ACF-2015-25-002). DTA was funded by an NIHR Doctoral Research

Fellowship (DRF-2018-11-ST2-065). The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care.

DATA SHARING

The data used in this study are sensitive and cannot be made publicly available without breaching patient confidentiality rules. Therefore, individual participant data and a data dictionary is not available to other researchers.

344 TABLES

345 Table 1: Clinical features of patients with pneumococcal parapneumonic effusions

CI 4 1 1	4 77	CDE		
Characteristic	All SPE		Pleural infection	P value *
	parapneumonic effusions		(N_100)	
	(N=559)	(N-450)	(N=100)	
Microbiological Confirmation of II	` /	(N=459)		
Blood culture	283 (51)	236 (51)	47 (47)	0.469
Urinary antigen test	276 (49)	223 (49)	55 (55)	0.407
Pleural Fluid Culture Results	270 (49)	223 (49)	33 (33)	0.277
S. pneumoniae positive	42 (8)	0 (0)	42 (42)	< 0.001
Multi-organism positive	15 (3)	0 (0)	15 (15)	< 0.001
Demographics	13 (3)	0 (0)	13 (13)	<0.001
Male – N (%)	282 (50)	223 (49)	56 (56)	0.205
Female – N (%)	277 (50)	236 (51)	44 (44)	0.205
` '	` /		` '	
Age (years) – median (IQR)	68 (50-78)	69 (57-78)	55 (45-74)	<0.001
Smoking Status - N (%)	127 (22)	106 (22)	21 (21)	0.722
Non-smoker	127 (23)	106 (23)	21 (21)	0.732
Current smoker	196 (35)	148 (32)	46 (46)	0.043
Ex-smoker	238 (43)	205 (45)	33 (33)	0.043
Comorbidities – N (%)				
Chronic Lung Disease	245 (44)	201 (43)	44 (44)	0.856
Cardiac Disease	304 (54)	261 (57)	43 (43)	0.011
Upper GI/S wallow Problem	214 (38)	180 (40)	34 (34)	0.265
Cerebrovascular Disease	39 (7)	29 (6)	10 (10)	0.148
Type 2 Diabetes	95 (17)	79 (17)	16 (16)	0.809
Chronic Liver Failure	25 (4)	21 (5)	4 (4)	0.672
Intravenous Drug Usage	24 (4)	17 (4)	7 (7)	0.192
Alcohol excess	53 (9)	38 (8)	15 (15)	0.028
BMI ≤17 or BMI ≥ 35	23 (4)	16 (3)	7 (7)	0.056
CURB65 Score on Admission	T	1		T
0 N(%)	28 (5)	20 (4)	8 (8)	0.088
1 N(%)	107 (19)	83 (18)	24 (24)	0.167
2 N(%)	139 (25)	112 (24)	27 (27)	0.528
3-5 N (%)	285 (51)	244 (53)	42 (42)	0.046
Investigation Results - median (IQ		T		T
White cell count,×10 ⁹ /L	17.8 (12.1-23.8)	17.0 (12.0-22.7)	20.8 (13.9-27.0)	0.005
Neutrophil count, ×10 ⁹ /L	14.9 (10.0-20.2)	14.2 (9.9-20.1)	18.5 (10.8-24.1)	0.003
C-reactive protein, mg/dL	215 (133-341)	200 (129-312)	331 (213-412)	< 0.001
Albumin, g/L	30 (26-36)	31 (27-36)	29 (23-34.3)	0.666
Urea, mmol/L	9.3 (6.4-13.2)	9.2 (6.5-13.3)	9.7 (6.1-12.8)	0.666
Outcomes - N (%)				T
Acute renal failure †	198 (35)	170 (37)	28 (28)	0.088
Liver dysfunction #	60 (11)	55 (12)	5 (5)	0.041
ITU admission	110 (20)	92 (20)	18 (18)	0.649
Increased care needed	198 (35)	176 (38)	22 (22)	0.002
Admission days – median (IQR)	11 (6-20)	10 (5-20)	14 (10-21)	< 0.001
Mortality				
- Inpatient mortality	71 (13)	60 (13)	11 (11)	0.586
- 30-day mortality	74 (13)	65 (14)	9 (9)	0.180
- 90-day mortality	106 (19)	94 (21)	12 (12)	0.039

- 1-y	ear mortality	150 (26)	134 (29)	16 (16)	0.008			
346								
347	* P-values represent the result of comparison between SPE and pleural infection groups with							
348	either Fisher's exact test (categorical variables) or the Mann-Whitney U-test (non-parametric							
349	continuous variables)							
350	† Acute renal failure was defined as a reduction in renal function (as measured by creatinine							
351	or eGFR), oliguria (<400ml urine per 24h) or clinical diagnosis of acute kidney injury							
352	2 # Liver dysfunction was defined as a transient disorder of hepatic function characterized by							
353	either liver enzymes, or clinical diagnosis of acute liver dysfunction. Other features of acute							
354	liver failure may or may not be present, including jaundice, vomiting, coagulopathy,							
355	hyperbilirubinemia, and incr	eased serum lactate	e					
356								

Table 2: Clinical features of patients with serotype 1 and 3 pneumococcal parapneumonic effusions

Characteristic	Serotype 1 N = 22	Serotype 3 N = 30	P value
Demographics – N (%)			
Male	13 (59)	16 (53)	0.181
Smoking			
- Current	11 (50)	11 (37)	0.353
- Ex-Smoker	5 (23)	12 (40)	0.201
Age – median (IQR)			
Age (years)	45 (40-69)	75 (62-83)	0.023
Comorbidities – N (%)			
Chronic Lung Disease	10 (46)	12 (40)	0.669
Cardiac Disease	9 (41)	21 (70)	0.038
Upper GI/Swallow Problem	3 (14)	13 (43)	0.027
Cerebrovascular Disease	3 (14)	5 (17)	0.771
Type 2 Diabetes	3 (14)	7 (23)	0.420
Chronic Liver Failure	0 (0)	2 (7)	0.210
Intravenous Drug Usage	1 (5)	1 (3)	0.714
Alcohol excess	2 (9)	4 (13)	0.656
Pleural Features – N (%)			
Pleural Infection	11 (50)	10 (33)	0.221
Loculation	5 (23)	3 (10)	0.205
Pus	4 (18)	6 (20)	0.858
RAPID Group			
- Low	10 (45)	4 (13)	0.011
- Medium	1 (5)	20 (67)	< 0.001
- High	9 (41)	3 (13)	0.024
Outcomes – N (%)			
Acute renal failure †	9 (41)	23 (78)	0.007
Liver dysfunction #	2 (9)	1 (3)	0.355
ITU admission	4 (18)	6 (20)	0.858
Increased care needed	6 (27)	10 (33)	0.646
30-day mortality	2 (9)	6 (20)	0.282
90-day mortality	3 (14)	11 (37)	0.068
365-day mortality	3 (14)	14 (47)	0.019
Admission days - median (IQR)	11 (5-21)	10 (4-18)	0.368

† Acute renal failure was defined as a reduction in renal function (measured by creatinine or eGFR), oliguria (<400ml urine per 24h) or clinical diagnosis of acute kidney injury # Liver dysfunction was defined as a transient disorder of hepatic function characterized by either liver enzymes, or clinical diagnosis of acute liver dysfunction. Other features of acute liver failure may or may not be present.

Table 3: Mortality among 100 Pneumococcal Pleural Infection cases with different clinical features and RAPID severity Scores

	Pleural Infection				
Characteristic	Total Patients (N=100)	30 Day Mortality N (%)	90 Day Mortality N (%)	365 Day Mortality N (%)	
Disease Characteristics					
Pus	59	0 (0)	0 (0)	1 (2)	
No Pus	41	9 (22)	12 (29)	12 (29)	
Loculation Present	49	8 (16)	10 (20)	12 (25)	
No loculation Detected	51	1 (2)	2 (4)	5 (10)	
Fibrinolytics used	33	4 (12)	6 (18)	11 (33)	
Surgical Management	29	0 (0)	0 (0)	0 (0)	
- Loculation present	23	0 (0)	0 (0)	0 (0)	
- No loculation	6	0 (0)	0 (0)	0 (0)	
No Surgical Management	71	9 (13)	12 (17)	17 (24)	
RAPID Risk Group					
Low	36	1 (3)	1 (3)	3 (8)	
Medium	46	2 (4)	3 (7)	4 (9)	
High	18	6 (33)	10 (55)	13 (72)	

RAPID (Renal, Age, Purulence, Infection source, and Dietary factors) Score 0-2 represents low risk, 3-4 medium risk and 5-7 high risk

Table 4: Cox Regression Analysis for risk factors in patients with pleural infection

Analysis	Factor	Wald	HR	<i>P</i> -value	95% CI
	Age	0.167	0.99	0.683	0.95-1.03
30-day mortality	Loculation	2.214	2.86	0.181	0.52-33.2
	RAPID Group	1.790	4.15	0.137	0.72-11.37
90-day mortality	Age	0.092	0.99	0.761	0.956-1.03
	Loculation	3.965	2.92	0.172	0.63-13.53
	RAPID Group	1.865	4.11	0.046	1.02-16.54
365-day mortality	Age	0.167	0.99	0.713	0.96-1.03
	Loculation	2.214	1.44	0.505	0.50-4.16
	RAPID Group	1.790	3.17	0.012	1.29-7.79

REFERENCES

- 375 1. UKHSA. Pneumococcal: the Green book. 2020; pp. 1-13.
- Whitney CG, Farley MM, Hadler J, Harrison LH, Bennett NM, Lynfield R, Reingold A, Cieslak
- PR, Pilishvili T, Jackson D, Facklam RR, Jorgensen JH, Schuchat A. Decline in Invasive Pneumococcal
- Disease after the Introduction of Protein–Polysaccharide Conjugate Vaccine. *New England Journal of Medicine* 2003: 348(18): 1737-1746.
- 380 3. Harboe ZB, Dalby T, Weinberger DM, Benfield T, Mølbak K, Slotved HC, Suppli CH, Konradsen
- 381 HB, Valentiner-Branth P. Impact of 13-Valent Pneumococcal Conjugate Vaccination in Invasive
- Pneumococcal Disease Incidence and Mortality. Clinical Infectious Diseases 2014: 59(8): 1066-1073.
- 383 4. Kelly MM, Coller RJ, Kohler JE, Zhao Q, Sklansky DJ, Shadman KA, Thurber A, Barreda CB,
- 384 Edmonson MB. Trends in Hospital Treatment of Empyema in Children in the United States. *The*
- 385 *Journal of Pediatrics* 2018: 202: 245-251.e241.
- 386 5. Weinberger DM, Harboe ZB, Shapiro ED. Developing Better Pneumococcal Vaccines for
- 387 Adults. *JAMA Internal Medicine* 2017: 177(3): 303-304.
- 388 6. Ladhani SN, Collins S, Djennad A, Sheppard CL, Borrow R, Fry NK, Andrews NJ, Miller E,
- Ramsay ME. Rapid increase in non-vaccine serotypes causing invasive pneumococcal disease in
- 390 England and Wales, 2000-2013;17: a prospective national observational cohort study. The Lancet
- 391 Infectious Diseases 2018: 18(4): 441-451.
- 392 7. Miller E, Andrews NJ, Waight PA, Slack MP, George RC. Herd immunity and serotype
- replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales:
- an observational cohort study. Lancet Infect Dis 2011: 11(10): 760-768.
- Waight PA, Andrews NJ, Ladhani SN, Sheppard CL, Slack MPE, Miller E. Effect of the 13-
- valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study. *Lancet Infect Dis* 2015: 15(5): 535-543.
- Pick H, Daniel P, Rodrigo C, Bewick T, Ashton D, Lawrence H, Baskaran V, Edwards-Pritchard
- 399 RC, Sheppard C, Eletu SD, Rose S, Litt D, Fry NK, Ladhani S, Chand M, Trotter C, McKeever TM, Lim
- WS. Pneumococcal serotype trends, surveillance and risk factors in UK adult pneumonia, 2013–18.
- 401 Thorax 2020: 75(1): 38.
- 402 10. Vallés X, Marcos A, Pinart M, Piñer R, Marco F, Mensa JM, Torres A. Hospitalized
- 403 Community-Acquired Pneumonia Due to Streptococcus pneumoniae: Has Resistance to Antibiotics
- 404 Decreased? Chest 2006: 130(3): 800-806.
- 405 11. Cillóniz C, Ewig S, Polverino E, Muñoz-Almagro C, Marco F, Gabarrús A, Menéndez R, Mensa
- J, Torres A. Pulmonary complications of pneumococcal community-acquired pneumonia: incidence,
- 407 predictors, and outcomes. Clinical Microbiology and Infection 2012: 18(11): 1134-1142.
- 408 12. Chalmers JD, Singanayagam A, Murray MP, Scally C, Fawzi A, Hill AT. Risk factors for
- 409 complicated parapneumonic effusion and empyema on presentation to hospital with community-
- 410 acquired pneumonia. *Thorax* 2009: 64(7): 592.
- 411 13. Wagenvoort GHJ, Sanders EAM, Vlaminckx BJ, Elberse KE, de Melker HE, van der Ende A,
- 412 Knol MJ. Invasive pneumococcal disease: Clinical outcomes and patient characteristics 2-6 years
- 413 after introduction of 7-valent pneumococcal conjugate vaccine compared to the pre-vaccine period,
- 414 the Netherlands. *Vaccine* 2016: 34(8): 1077-1085.
- 415 14. Falguera M, Carratalà J, Bielsa S, García-Vidal C, Ruiz-González A, Chica I, Gudiol F, Porcel JM.
- 416 Predictive factors, microbiology and outcome of patients with parapneumonic effusion. European
- 417 Respiratory Journal 2011: 38(5): 1173.
- 418 15. Hyams C, Amin-Chowdhury Z, Fry NK, North P, Finn A, Judge A, Ladhani SN, Williams OM.
- Streptococcus Pneumoniae septic arthritis in adults in Bristol and Bath, United Kingdom, 2006–2018:
- 420 a 13-year retrospective observational cohort study. Emerging Microbes & Infections 2021: 10(1):
- 421 1369-1377.
- 422 16. Amin-Chowdhury Z, Collins S, Sheppard C, Litt D, Fry NK, Andrews N, Ladhani SN.
- 423 Characteristics of Invasive Pneumococcal Disease Caused by Emerging Serotypes After the

- 424 Introduction of the 13-Valent Pneumococcal Conjugate Vaccine in England: A Prospective
- 425 Observational Cohort Study, 2014–2018. Clinical Infectious Diseases 2020.
- 426 17. Lim WS, van der Eerden MM, Laing R, Boersma WG, Karalus N, Town GI, Lewis SA,
- 427 Macfarlane JT. Defining community acquired pneumonia severity on presentation to hospital: an
- international derivation and validation study. *Thorax* 2003: 58(5): 377.
- 429 18. Rahman NM, Kahan BC, Miller RF, Gleeson FV, Nunn AJ, Maskell NA. A Clinical Score (RAPID)
- 430 to Identify Those at Risk for Poor Outcome at Presentation in Patients With Pleural Infection. Chest
- 431 2014: 145(4): 848-855.
- 432 19. Corcoran JP, Psallidas I, Gerry S, Piccolo F, Koegelenberg CF, Saba T, Daneshvar C, Fairbairn I,
- 433 Heinink R, West A, Stanton AE, Holme J, Kastelik JA, Steer H, Downer NJ, Haris M, Baker EH, Everett
- 434 CF, Pepperell J, Bewick T, Yarmus L, Maldonado F, Khan B, Hart-Thomas A, Hands G, Warwick G, De
- Fonseka D, Hassan M, Munavvar M, Guhan A, Shahidi M, Pogson Z, Dowson L, Popowicz ND, Saba J,
- Ward NR, Hallifax RJ, Dobson M, Shaw R, Hedley EL, Sabia A, Robinson B, Collins GS, Davies HE, Yu L-
- 437 M, Miller RF, Maskell NA, Rahman NM. Prospective validation of the RAPID clinical risk prediction
- score in adult patients with pleural infection: the PILOT study. European Respiratory Journal 2020:
- 439 2000130.
- 440 20. Houseman C, Hughes GJ, Chapman KE, Wilson D, Gorton R. Increased Invasive Pneumococcal
- Disease, North East England, UK. Emerg Infect Dis 2017: 23(1): 122-126.
- 442 21. Abram SGF, Alvand A, Judge A, Beard DJ, Price AJ. Mortality and adverse joint outcomes
- 443 following septic arthritis of the native knee: a longitudinal cohort study of patients receiving
- arthroscopic washout. *The Lancet Infectious Diseases* 2020: 20(3): 341-349.
- 445 22. Finley C, Clifton J, Fitzgerald JM, Yee J. Empyema: an increasing concern in Canada. Can
- 446 Respir J 2008: 15(2): 85-89.
- 447 23. Mummadi SR, Stoller JK, Lopez R, Kailasam K, Gillespie CT, Hahn PY. Epidemiology of Adult
- 448 Pleural Disease in the United States. *Chest* 2021: 160(4): 1534-1551.
- 449 24. Søgaard M, Nielsen RB, Nørgaard M, Kornum JB, Schønheyder HC, Thomsen RW. Incidence,
- 450 Length of Stay, and Prognosis of Hospitalized Patients With Pleural Empyema: A 15-Year Danish
- 451 Nationwide Cohort Study. *Chest* 2014: 145(1): 189-192.
- 452 25. Arnold DT, Hamilton FW, Morris TT, Suri T, Morley A, Frost V, Vipond IB, Medford AR, Payne
- 453 RA, Muir P, Maskell NA. Epidemiology of pleural empyema in English hospitals and the impact of
- 454 influenza. European Respiratory Journal 2020: 2003546.
- 455 26. Maguire D, Dunn P, McKenna H. How hospital activity in the NHS in England has changed
- 456 over time. 2016.
- 457 27. Fletcher MA, Schmitt HJ, Syrochkina M, Sylvester G. Pneumococcal empyema and
- 458 complicated pneumonias: global trends in incidence, prevalence, and serotype epidemiology.
- 459 European Journal of Clinical Microbiology & Infectious Diseases 2014: 33(6): 879-910.
- 460 28. Brueggemann AB, Griffiths DT, Meats E, Peto T, Crook DW, Spratt BG. Clonal Relationships
- 461 between Invasive and Carriage Streptococcus pneumoniae and Serotype- and Clone-Specific
- 462 Differences in Invasive Disease Potential. *The Journal of Infectious Diseases* 2003: 187(9): 1424-1432.
- 463 29. Weinberger DM, Harboe ZB, Sanders EAM, Ndiritu M, Klugman KP, Rückinger S, Dagan R,
- Adegbola R, Cutts F, Johnson HL, O'Brien KL, Scott JA, Lipsitch M. Association of Serotype with Risk of
- 465 Death Due to Pneumococcal Pneumonia: A Meta-Analysis. Clinical Infectious Diseases 2010: 51(6):
- 466 692-699.
- 467 30. Hyams C, Yuste J, Bax K, Camberlein E, Weiser JN, Brown JS. Streptococcus pneumoniae
- 468 resistance to complement-mediated immunity is dependent on the capsular serotype. Infect Immun
- 469 2010: 78(2): 716-725.
- 470 31. Kaushal N, Kumari S, Jhelum H, Sehgal D. In vitro and in vivo characterization of the
- 471 interaction, proinflammatory, immunomodulatory and antigenic properties of capsular
- 472 polysaccharide from Streptococcus pneumoniae serotype 1. International Journal of Biological
- 473 *Macromolecules* 2020: 143: 521-532.

- 474 32. Bergman K, Härnqvist T, Backhaus E, Trollfors B, Dahl MS, Kolberg H, Ockborn G, Andersson
- 475 R, Karlsson J, Mellgren Å, Skovbjerg S. Invasive pneumococcal disease in persons with predisposing
- factors is dominated by non-vaccine serotypes in Southwest Sweden. *BMC Infectious Diseases* 2021:
- 477 21(1): 756.
- 478 33. Luck JN, Tettelin H, Orihuela CJ. Sugar-Coated Killer: Serotype 3 Pneumococcal Disease.
- 479 Frontiers in Cellular and Infection Microbiology 2020: 10.
- 480 34. Pande A, Nasir S, Rueda AM, Matejowsky R, Ramos J, Doshi S, Kulkarni P, Musher DM. The
- 481 Incidence of Necrotizing Changes in Adults With Pneumococcal Pneumonia. Clinical Infectious
- 482 Diseases 2012: 54(1): 10-16.
- 483 35. Azarian T, Mitchell PK, Georgieva M, Thompson CM, Ghouila A, Pollard AJ, von Gottberg A,
- du Plessis M, Antonio M, Kwambana-Adams BA, Clarke SC, Everett D, Cornick J, Sadowy E,
- 485 Hryniewicz W, Skoczynska A, Moïsi JC, McGee L, Beall B, Metcalf BJ, Breiman RF, Ho PL, Reid R,
- O'Brien KL, Gladstone RA, Bentley SD, Hanage WP. Global emergence and population dynamics of
- divergent serotype 3 CC180 pneumococci. PLOS Pathogens 2018: 14(11): e1007438.
- 488 36. Croucher NJ, Mitchell AM, Gould KA, Inverarity D, Barquist L, Feltwell T, Fookes MC, Harris
- SR, Dordel J, Salter SJ, Browall S, Zemlickova H, Parkhill J, Normark S, Henriques-Normark B, Hinds J,
- 490 Mitchell TJ, Bentley SD. Dominant Role of Nucleotide Substitution in the Diversification of Serotype 3
- 491 Pneumococci over Decades and during a Single Infection. PLOS Genetics 2013: 9(10): e1003868.
- 492 37. Groves N, Sheppard CL, Litt D, Rose S, Silva A, Njoku N, Rodrigues S, Amin-Chowdhury Z,
- 493 Andrews N, Ladhani S, Fry NK. Evolution of Streptococcus pneumoniae Serotype 3 in England and
- 494 Wales: A Major Vaccine Evader. *Genes* 2019: 10(11).
- 495 38. Cargill TN, Hassan M, Corcoran JP, Harriss E, Asciak R, Mercer RM, McCracken DJ, Bedawi EO,
- 496 Rahman NM. A systematic review of comorbidities and outcomes of adult patients with pleural
- infection. European Respiratory Journal 2019: 1900541.
- 498 39. White HD, Henry C, Stock EM, Arroliga AC, Ghamande S. Predicting Long-Term Outcomes in
- 499 Pleural Infections. RAPID Score for Risk Stratification. *Annals of the American Thoracic Society* 2015:
- 500 12(9): 1310-1316.
- 501 40. Hyams C, Williams OM, Williams P. Urinary antigen testing for pneumococcal pneumonia: is
- there evidence to make its use uncommon in clinical practice? ERJ Open Research 2020: 6(1): 00223-
- 503 02019.

Figure One: Study Cohort Pagults from 3677 microbiology

Results from 3677 microbiology database occurrences of a positive blood or urine antigen test were identified. There were 2657 cases of pneumococcal infection in adults, including 559 patients with parapneumonic effusions.





Figure 2: Vaccine group serotype trends in pneumococcal parapneumonic effusions in Bristol, UK 2006-2018

(A) Incidence* of pneumococcal parapneumonic effusion, per 100,000 adults, and (B) proportions of serotyped disease caused by serotypes grouped by vaccine as shown from 2006-2018. Dashed lines show the introductions of paediatric PCV7 and PCV13.

*Calculated using adult population data from the Office of National Statistics (Supplementary Data 4).









Figure 3: 1-year survival in patients with pneumococcal parapneumonic effusions

(A) Kaplan-Meier survival curve and number at risk for patients with simple parapneumonic effusion (SPE) (red line) and pleural infection (blue line). (B) Kaplan-Meier survival curve and number at risk for patients with pneumococcal pleural infection for low (red line), medium (blue line) and high (black line) RAPID score groups. The number of subjects at risk immediately before each time point is listed in a numbers-at-risk table







Days	0	50	112	154	280	310	365
Low	30	30	30	30	30	29	29
Medium	50	48	47	47	47	47	47
High	14	8	7	6	5	4	4